Cempra wins $58M BARDA contract for lead antibiotic

Chapel Hill, NC-based Cempra ($CEMP) has won a $58 million contract from BARDA to develop its lead, late-stage antibiotic for bioterror threats aimed at a pediatric population. Solithromycin is a next-gen macrolide antibiotic in the fluoroketolide family currently in Phase III development for community-acquired bacterial pneumonia in adults. "We view BARDA's funding of this project as recognition of the potential of solithromycin to have broad utility in all age groups," said Cempra CEO Prabhavathi Fernandes. Release

Suggested Articles

The deal gives J&J a stake in the development and commercialization of anticoagulants including phase 2-ready secondary stroke candidate BMS-986177.

Boehringer gained the global rights to OSE's SIRP-alpha antagonist, which is in development for solid tumors.

Lilly is diving into encapsulated beta cell treatments, designed to restore insulin production in patients with Type 1 diabetes.